Clinical Trial Update: Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 multicenter trial of intrathecal HGT-1110 in children with metachromatic leukodystrophy (MLD) completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metachromatic Leukodystrophy

Drugs mentioned

• HGT-1110

Snippet

Sponsor: Shire | Conditions: Metachromatic Leukodystrophy (MLD) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-10-15